Status:

COMPLETED

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

Lead Sponsor:

Biogen

Conditions:

Depression, Postpartum

Eligibility:

FEMALE

18-45 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.

Detailed Description

This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.

Eligibility Criteria

Inclusion

  • Participant has ceased lactating or agrees not to provide breastmilk to her infant(s) from just prior to receiving the investigational product (IP) on Day 1 until 7 days after the last dose of IP.
  • Participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Diagnostic and DSM-5 Clinical Trial Version (SCID-5-CT).
  • Participant is ≤12 months postpartum at screening and Day 1.

Exclusion

  • Participant is at significant risk of suicide or has attempted suicide associated with the current episode of PPD.
  • Participant has active psychosis per investigator assessment.
  • Participant has a medical history of nonfebrile seizures.
  • Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
  • Participant has a history of sleep apnea.
  • Note: Other protocol-defined inclusion/exclusion criteria applied.

Key Trial Info

Start Date :

June 8 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 12 2022

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT04442503

Start Date

June 8 2020

End Date

April 12 2022

Last Update

November 30 2023

Active Locations (82)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 21 (82 locations)

1

Sage Investigational Site

Scottsdale, Arizona, United States, 85258

2

Sage Investigational Site

Bentonville, Arkansas, United States, 72712

3

Sage Investigational Site

Anaheim, California, United States, 92805

4

Sage Investigational Site

Bellflower, California, United States, 90706